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severity is a common source of bias. Consequently, failure to properly control for the 
bias could lead to serious ﬂ aws in the study. METHODS: We used a novel approach 
for identifying comorbidities associated with COPD by mapping the incident comor-
bidity patterns in the pre-COPD diagnosis period as well as over the course of the 
disease using a retrospective cohort of patients aged 50+ in the UK General Practice 
Research Database. Each patient was matched to another without COPD on year of 
birth, sex, general practice and completed years of medical records up to at least a 
year after the index date for COPD between 1990 and 1998. We identiﬁ ed 24,000 
such pairs that also satisﬁ ed a requirement for at least one medical consultation and 
at least one prescription for any drug in the year prior to the index date for COPD. 
RESULTS: Based on trends in rate ratios, we found signiﬁ cant time-dependent associa-
tions between the incident COPD diagnosis and incident comorbid conditions such as 
lung cancer, myocardial infarction, pneumonia, cardiac disorders, osteoporosis, frac-
tures, skin bruises, psychiatric disorders and respiratory infections. CONCLUSIONS: 
The results indicated interesting associations which could help improve our under-
standing of the natural history of COPD and its burden. This methodology can be 
used to identify important comorbidities for effective comparative assessments.
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OBJECTIVES: The objective of this study was to estimate the effectiveness of vareni-
cline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in two 
specialized smoking units belonging to primary care centers. METHODS: A multi-
center longitudinal observational study was designed. Patient’s data were collected 
retrospectively based on their clinical records. Patients over the age of 18, who initi-
ated treatment of smoking cessation between January 1, 2006 and January 12, 2008 
with varenicline, bupropion or NRT were included in the analysis. Patient’s follow-up 
was conducted from time-baseline (day 1) and assessed at 6 and 12 months. Main 
variables included in the study were: comorbidities, effectiveness (continuous absti-
nence) and pharmacological tolerability. Statistical analysis was performed by Kaplan-
Maier survival curves; P < 0.05. RESULTS: A total of 957 smokers patients treated 
with NRT (53.0%), bupropion (25.1%) and varenicline (21.9%) were included in the 
analysis. The mean age of participants was 47.6 (11.3) years and 58.6% were men. 
The average duration of smoking was 19.5 (6.7) years. At 6 months, 61.2% (95% 
CI: 54.6–67.8%) of participants in the varenicline group were continuously abstinent 
from smoking compared with 56.9% (95% CI: 50.6–63.2%) in the bupropion group 
and 52.3% (95% CI: 48.0–56.6%) in the NRT group; p = 0.003. At 12 months, the 
rate of continuous abstinence was 57.4% (95% CI: 50.7–64.1%) in the varenicline 
group compared with 52.9% (95% CI: 46.6–59.2%) in the bupropion group and 
47.1% (95% CI: 42.8–51.4%) in the NRT group; p = 0.002. Pharmacological toler-
ability was similar between groups except for symptoms of irritability which were 
lower in the varenicline group: 4.3% compared to 8.3% in the bupropion group and 
10.3% in the NRT group. CONCLUSIONS: Varenicline appeared to be an effective 
and safety alternative compared with bupropion and NRT on smoking cessation in 
the primary care setting.
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OBJECTIVES: Use of triple therapy (long-acting beta2 agonist [LABA], inhaled corti-
costeroid [ICS] and long-acting muscarinic antagonist [LAMA]) for the treatment of 
COPD has doubled in the UK over the past 5 years for all severities of the disease. 
This research was designed to compare the two most commonly prescribed combina-
tion inhalers (BUD/FORM and SALM/FLU) as the basis of triple therapy with TIO, 
the most widely used LAMA. METHODS: Systematic review of CENTRAL, EMBASE 
and MEDLINE for randomised controlled trials (RCTs) in patients with COPD treated 
with BUD/FORM+TIO or SALM/FLU+TIO was conducted in May 2010. Mixed 
treatment comparison (MTC) using TIO as a common comparator was conducted 
using a Bayesian Markov Chain Monte Carlo simulation. Fixed- and random-effects 
models were explored with the preferred model selected based on the Deviance Infor-
mation Criterion (DIC). Data was extracted from relevant trials on severe exacerba-
tions (a composite of oral corticosteroids, hospitalizations and A&E visits due to 
worsening symptoms). Summary effect estimate was calculated as odds ratio (OR) 
with 95% credible interval (95% CrI) where OR < 1 favoured BUD/FORM+TIO and 
OR > 1 favoured SALM/FLU+TIO. RESULTS: Of the 124 papers identiﬁ ed in the 
literature search, 3 RCTs had comparable patient populations and were able to supply 
data for analysis (1 BUD/FORM+TIO [N = 660] and 2 SALM/FLU+TIO [N = 301 
and N = 60]). The exclusion of papers was based on not meeting all of the following 
inclusion critieria: RCTs of the chosen comparators; COPD patient population; 
reporting exacerbations; English-language full publication; and non-duplicates. When 
the ﬁ xed- and random-effects MTC models were compared the ﬁ xed-effects MTC had 
the lowest DIC. The results indicate a 55% relative reduction in severe exacerbations 
with BUD/FORM+TIO compared to SALM/FLU+TIO (OR 0.45, 95% CrI: 0.22 to 
0.83). CONCLUSIONS: This MTC suggests that BUD/FORM-based triple therapy is 
signiﬁ cantly more effective at reducing severe exacerbations than SALM/FLU-based 
triple therapy.
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OBJECTIVES: Modeling a chronic disease like COPD is useful to extrapolate (inter-
mediate) treatment effects observed in short-term randomized trials to the medium or 
long term. This study aimed to extend an existing dynamic population model of COPD 
progression by including exacerbations and making the model stochastic. METHODS: 
The COPD model starts with COPD prevalence in the Dutch population speciﬁ ed by 
age, gender, disease severity (four severity stages) and smoking status. Each following 
year the model simulates the changes in the prevalence and COPD-related health care 
costs due to incidence, mortality and disease progression, i.e. annual decline in FEV1% 
predicted.The structure was adjusted to include moderate and severe exacerbations 
and the following input parameters were estimated by quantitative meta-analyses: the 
frequency, case-fatality, lung function decline, quality of life loss and costs of exacerba-
tions. The model was made stochastic by specifying probability distributions around 
all important model parameters. The adapted model can be used to assess the impact 
of interventions that inﬂ uence COPD incidence, disease progression, frequency and/or 
severity of exacerbations, mortality, quality of life or combinations of these effects. To 
illustrate the potential use of the model, long- term costs and effects were projected 
for four different COPD interventions, two on pharmacotherapy, one on smoking 
cessation therapy and one on pulmonary rehabilitation. RESULTS: Compared to a 
reference scenario representing minimal treatment, the cost-effectiveness of the four 
interventions ranged from c6,100 to c12,200 per QALY gained. The probability of 
the interventions to be cost-effective at a ceiling ratio of c20,000 varied from X to 
Y%. CONCLUSIONS: The extended COPD model can provide policy makers with 
information about long-term costs and effects of interventions over the entire chain, 
from primary prevention to care for very severe COPD. Moreover it describes the 
uncertainty of the outcomes.
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OBJECTIVES: This study compared efﬁ cacy and safety of ciclesonide (CIC) with 
ﬂ uticasone (FP) in the treatment of bronchial asthma. METHODS: Comparison was 
based on randomized controlled trials (RCTs) identiﬁ ed by means of systematic 
review, carried out according to the Cochrane Collaboration guidelines. The most 
important medical databases (EMBASE, MEDLINE, CENTRAL) were searched. Two 
reviewers independently selected trials, assessed their quality and extracted data. 
Meta-analysis of head-to-head trials was performed. RESULTS: Ten RCTs directly 
comparing CIC vs. FP were identiﬁ ed and included in the analysis. Comparisons of 
both interventions in 1:1 and 1:2 dose ratios were assessed in 8 and 5 trials, respec-
tively. Efﬁ cacy of CIC was comparable to FP in both, 1:1 and 1:2 dose ratios with 
respect to reduction in risk of asthma exacerbations, improvement in proportion of 
symptom-free days, rescue medication-free days and improvement in asthma symp-
toms. Moreover, CIC and FP showed similar improvement in spirometric parameters. 
Comparison between CIC and FP in 1:1 dose ratio revealed that treatment with CIC 
was associated with statistically signiﬁ cant risk reduction of adverse events possibly 
related to study medication (RR = 0.57 [0.39; 0.83]; NNT = 16.89 [10.24; 48.18]) 
and candidosis (RR = 0.31 [0.17; 0.56], NNT = 32.74 [22.23; 61.99]), while the 
differences between groups were not signiﬁ cant for 1:2 dose ratio. There were no 
statistically signiﬁ cant differences between CIC and FP in either dose ratio with respect 
to the risk of any adverse events, upper respiratory tract infections, pharyngitis and 
dysphonia. CONCLUSIONS: Ciclesonide is a therapeutic option for patients with 
bronchial asthma showing comparable efﬁ cacy to ﬂ uticasone in both 1:1 and 1:2 dose 
ratios and provides concomitant risk reduction of candidosis and adverse events 
related to study medication.
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OBJECTIVES: This study compared efﬁ cacy and safety of ciclesonide (CIC) with 
budesonide (BUD) in the treatment of bronchial asthma. METHODS: Comparison 
was based on randomized controlled trials (RCTs) identiﬁ ed by means of systematic 
review, carried out according to the Cochrane Collaboration guidelines. The most 
important medical databases (EMBASE, MEDLINE, CENTRAL) were searched. Two 
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reviewers independently selected trials, assessed their quality and extracted data. 
Meta-analysis of head-to-head trials was performed. RESULTS: Seven RCTs compar-
ing CIC vs. BUD were identiﬁ ed and included in the analysis. Comparisons of both 
interventions in 1:1 and 1:2 dose ratios were assessed in 3 and 4 trials, respectively. 
CIC as compared with BUD in 1:1 dose ratio was associated with signiﬁ cant improve-
ment in forced vital capacity (FVC) and peak expiratory ﬂ ow (PEF) by spirometry 
(WMD = 0.09 [0.03; 0.14] and WMD = 19.00 [2.37; 35.63], respectively) as well as 
reduction in proportion of symptom-free days (p = 0.018). No statistically signiﬁ cant 
differences between both drugs in 1:2 dose ratios were observed. CIC and BUD in 
either dose showed comparable efﬁ cacy with respect to the risk of asthma exacerba-
tion, improvement in symptoms of asthma and forced expiratory volume in 1 second 
(FEV1). CIC-treated patients experienced less upper respiratory tract infections than 
those treated with BUD in 1:1 dose ratio, however the difference was on the border 
of statistical signiﬁ cance (RR = 0.65 [0.43; 0.99], NNT not signiﬁ cant). There were 
no statistically signiﬁ cant differences between CIC and BUD in either dose ratio with 
respect to risk of adverse events, adverse events related to study medication, pharyn-
gitis and dysphonia. CONCLUSIONS: Ciclesonide provides an improvement in spi-
rometric paramethers and reduction of asthma symptom-free days as compared to 
budesonide in 1:1 dose ratio, while no differences were noticed between CIC and BUD 
in 1:2 dose ratio. Safety proﬁ le of ciclesonide seems to be comparable with budesonide.
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OBJECTIVES: Current asthma management recommendations are based on the level 
of asthma control rather than disease severity. The ﬁ nancial impact associated with 
asthma control needs to be determined. The primary objective of this study was to 
estimate quality of life and health care costs according to the patients’ level of asthma 
control in France and in Spain. METHODS: An observational retrospective bottom-up 
cost of illness study was conducted in adults patients with asthma. Investigators were 
general practitioners. Asthma control was evaluated using the validated auto-test 
Asthma Control Test (ACTTM) for a one month period and 2009 GINA’s asthma 
control criteria for a three months period. Quality of life (QoL) was assessed using 
EQ-5D proﬁ le. Costs (direct and indirect) were evaluated from a societal perspective. 
RESULTS: 794 patients (France: 391; Spain: 403) were enrolled in the ﬁ rst quarterly 
wave of the survey. Based on the ACT, asthma was determined to be well-controlled 
(ACT ≥ 20) in 48.1% [IC 95%: 42.1%–54%] and 56.2% [IC95: 51.1%–61.2%] of 
French and Spanish patients respectively. In both countries, EQ-5D scores were 0.9 
and 0.7 in well-controlled and not well-controlled patients respectively (P < 0.0001). 
Total costs of asthma were directly related to asthma control in both countries. The 
average cost (Euros/month/patient) of well-controlled asthma was c28 (±36) in France 
and c77 (±105) in Spain compared with c140 (±782) (p = 0.0009) and c252 (±380) 
(p < 0.0001) respectively for not well-controlled asthma. Similar associations were 
observed using the latest GINA’s criteria. CONCLUSIONS: We found strong associa-
tions between asthma control level, costs and QoL in patients with asthma. Achieve-
ment of good clinical control of asthma may result in a signiﬁ cant decrease of the 
economic burden of asthma and a better health status in adults.
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OBJECTIVES: The prevalence of asthma has been reported to be increasing for 
decades, but recent studies suggest a leveling off or even decrease in prevalence among 
children. The objective of this study was to assess the trends in anti-asthma medication 
use in Dutch children from 1998 until 2007. METHODS: From the PHARMO Record 
Linkage System, an administrative database network of outpatient pharmacies, hos-
pitals, and other settings, including data of ~4 million individuals in deﬁ ned areas of 
the The Netherlands, we assessed 1) the proportion of children aged 0–19 years with 
at least one dispensing for short (SABA) or long-acting β2-antagonists (LABA), inhaled 
glucocorticoids (ICS), ﬁ xed dose combinations (FDC) of LABA and ICS or leukotriene 
receptor antagonists (LRTA) in the years 1998–2007 stratiﬁ ed by age groups, 2) the 
proportion of users per type for each year and 3) the age distribution per medication 
type for the year 2007. RESULTS: Overall prevalence of anti-asthma medication use 
was approximately 7% and remained stable between 1998 and 2007. Prevalence was 
highest among children aged 0–1 years and declined with increasing age. Over time, 
the prevalence remained stable in all age groups, except for the youngest in which it 
increased from 10% in 1998 to 19% in 2007. Use of ICS and LABA declined over 
time (user proportions: −17% and −3%), against increased use of LABA-ICS FDC and 
LRTA (+15% and +3%). Children <6 years made up relatively large proportions of 
SABA and ICS users, while the older children were more dominant in the other medica-
tion types. CONCLUSIONS: This study provides a comprehensive overview of trends 
in anti-asthma medication use in children showing no overall change in prevalence 
over time. However, a change in type of medication was observed. 
RESPIRATORY-RELATED DISORDERS – Cost Studies
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OBJECTIVES: To compare the impact of different pharmacotherapies on the cost of 
exacerbation of COPD in public hospitals in Hong Kong. METHODS: This was a 
retrospective study comparing the cost of management of chronic obstructive pulmo-
nary disease (COPD) in patients from a public hospital perspective in Hong Kong. 
Institutional ethics approval was obtained. The patients were above 65 years with a 
diagnosis of COPD of stage 3 or above based on the GOLD guideline. COPD was 
deﬁ ned based on ICD-9-CM codes. Two cohorts of patients were included: 1) Those 
who received ﬂ uticasone propionate and salmeterol, plus ipratropium bromide and 
salbutamol inhalation, and 2) Those who received ipratropium bromide and salbuta-
mol, and beclomethasone inhalation. Patients were followed for 6 months before and 
after medications. The date one of the therapies started was the index date. RESULTS: 
A total of 75 patients were recruited over January to June 2008. All values are 
expressed as mean ± SD. The number of emergency room visits and cost of visits 
before and after the index date for both cohorts did not show a signiﬁ cant difference 
(1.86 ± 2.5 days vs. 1.62 ± 1.93 days and HKD1061 ± 1442 vs. HKD924 ± 1102 for 
cohort 1, 1.15 ± 1.28 days vs. 1.02 ± 1.29 days and HKD657 ± 730 vs. HKD582 ± 
735 for cohort 2, p > 0.1). There was a trend of reduction in hospitalization days and 
cost of stay before and after the index date for cohort 1 (although not reaching a 
signiﬁ cant level) but not in cohort 2 (20.6 ± 28.4 days vs. 15.6 ± 18.8 days and 
HKD68162 ± 93875 vs. HKD51662 ± 66278 for cohort 1, 11.1 ± 13.5 days vs. 10.2 
± 13.2 days and HKD36730 ± 44604 vs. HKD33860 ± 43571 for cohort 2, p > 0.1). 
CONCLUSIONS: A trend of reduction in hospital stay was demonstrated (although 
not statistically signiﬁ cant) in patients after receiving combination therapy of ﬂ utica-
sone propionate and salmeterol plus ipratropium bromide and salbutamol. This is 
consistent with earlier studies in other countries. a larger number of patients is 
required to prove the signiﬁ cance of this ﬁ nding.
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OBJECTIVES: To analyze the GP’s prescriptions of bronchodilators for managing the 
patients with stable COPD, to compare the prescriptions with Ukrainian National 
COPD Management Guidelines. And we estimated the annual costs for bronchodila-
tors were used most frequently. METHODS: The analysis of prescription habits based 
on data from outpatient personal medical cards of 103 patients with COPD (2nd 
Municipal Clinic, Bila Tserkva, Ukraine), focused on bronchodilators as central medi-
cations for symptomatic treatment. Among 103 patients 15 were with mild COPD, 
75 with moderate and 13 with severe (according to GOLD). The prescriptions for 
regular treatment were compared with national guidelines. Annual medications costs 
were calculated based on the number of medicines units for 24 hour bronchodilation 
during a year, multiplied by the one unit price in UAH (1 EUR = 10.05 UAH). 
RESULTS: Regular basis was prescribed to 87 patients. Among 87 prescriptions 
13.7% were long-acting inhaled bronchodilators or combinations, 86.3% were short-
acting inhaled bronchodilators, methylexanthines or combinations. Ranking to a 
number of medicines were most frequently prescribed: 56.8% ﬁ xed combination 
Ipratropium/Fenoterol, 10.2% Tiotropium, 9.1% Fenoterol, 7.9% Salbutamol. 
Annual costs for these bronchodilators were: 1206.0, 6262.0, 1303.0 and 275.0 UAH, 
respectively. CONCLUSIONS: The most frequently prescribed bronchodilator was 
Ipratropium/Fenoterol. It’s available during decades and inexpensively. But its basis 
requires triple daily medication, in consequence of that persistency rate might be 
reduced with effectiveness reducing, respectively. Tiotropium ranked second in the 
prescription frequency. It has duration of action of more than 24 hours, high effective-
ness and safety levels but gets 6262.0 UAH annually. So the affordability of a bron-
chodilator is weighty criterion for Ukrainian GP’s prescriptions. But medications costs 
must be scrupulously compared with effectiveness for their including to the national 
formulary and reimbursement decision-making.
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OBJECTIVES: The aim of this study is to analyze the economic impact of non-
adherence to GOLD guidelines in COPD patients. METHODS: A retrospective analy-
sis was carried out in a claim database. Patients ≥40 years-old with diagnosis of COPD 
conﬁ rmed with spirometry (FEV1/FVC < 0.7) were eligible for this analysis. Patients 
were classiﬁ ed into two groups according to whether they fulﬁ ll with therapeutics 
recommendations by severity deﬁ ned in GOLD guidelines (GOLD group) or those 
who don’t fulﬁ ll (NO-GOLD group). Demographics, medical and use of resources 
data were collected and direct and indirect costs were analyzed. a probabilistic mul-
